Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosgosstrakh reported for 6 months of 2023 by RAS

7/25/23 RGSS

UAC reported for 6 months of 2023 by RAS

7/25/23 UNAC

The International Business Machines announced a quarterly dividend

7/25/23 IBM

Whoosh launches electric bicycle sharing in Kazakhstan

7/25/23 WUSH

NCSP reported for 6 months of 2023 by RAS

7/25/23 NMTP

NKHP reported for 6 months of 2023 by RAS

7/25/23 NKHP

Sber issued digital financial assets of developer Glavstroy

7/25/23 SBER

NextEra Energy reported for 6 months of 2023

7/25/23 NEE

The Wells Fargo & Co announced a quarterly dividend

7/25/23 WFC

Verizon reported for 6 months of 2023

7/25/23 VZ